ABOUT US

Diversified pharmaceutical company with divisions
for novel medicines and complex generics

ARBOMED HISTORY

2022

  • 05

    Series B Funding completed (15 billion KRW)

    Introduced the efficacy of ARBM-101 in Wilson's Disease (Wilson Aarhus 2022)

    Announced ARBM-201 as the candidate of ARDS therapeutics (ATS 2022)

2021

2020

2018

2017